Table 1.

Clinicopathologic characteristics of patients and cancers included in study

All patientsPatients assessable for RAD51
n 6857
Median age47 (29–67)48 (29–67)
 Invasive ductal carcinoma5345
 Invasive lobular carcinoma119
Median tumor size (range), mm51 (20–110)53 (21–110)
Axillary node positive54% (30/52)55% (25/45)
ER positive64% (41/64)63% (35/55)
HER2 positive19% (10/52)18% (9/49)
Menopausal status
Chemotherapy (35, 36)
 Doxorubicin, cyclophosphamide3628
 Fluorouracil, epirubicin, cyclophosphamide54
 Epirubicin, cisplatin, infusional fluorouracil1414
 Epirubicin, cyclophosphamide, infusional fluorouracil54
 Navelbine, epirubuicin87
Tamoxifen82% (48/58)79% (43/54)
Clinical response
 Stable disease127
 Progressive disease33
pathCR10% (6/60)10% (5/49)

NOTE: Eleven tumors had no proliferation in the postchemotherapy biopsy and were not assessable for RAD51.